Aim: The laboratory findings are non-specific in Rheumatoid arthritis (RA). We have based our study on this idea and chose cytokinesand chemokine to evaluate ; we then tried to establish a relationship between the progress of the disease and the levels of thesemolecules before and 3-6 months after the TNF-α blocker treatment.Material and Methods: A total of 34 RA patients (28 females, 6 males) who were diagnosed with RA and received TNF-α blockertherapy were included in the study.Blood samples were drawn from the patients before the TNF-α treatment began and then in thefollowing 3rd and 6th months of the treatment.Results: The mean age of the study group is 49.15±11.03. the mean disease period is 9.77±6.29 years and the mean treatment perio...
Artículo de publicación SCOPUSTumor necrosis factor (TNF) plays a pivotal role in the pathogenesis ...
Bacground/Aim. Experimental in vitro and in vivo investigations in a mouse model have proved that TN...
Introduction: Currently used clinical scale and laboratory markers to monitor patients with early ...
Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA)...
The aim of the investigation was to study the changes of cytokine profile parameters in patients wit...
OBJECTIVES: To determine the serum concentration of tumour necrosis factor (TNF)-related weak induce...
Background: An important characteristic of immune pathology in rheumatoid arthritis (RA) is a B-cell...
Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA)...
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects small join...
OBJECTIVES: To evaluate synovial tissue and serum biomarkers of disease activity, therapeutic respon...
<p>(<b>A</b>) Plasma levels of TNF-α in HCs, drug responders, and drug non-responders at baseline an...
<div><p>The inability to match rheumatoid arthritis (RA) patients with the anti-cytokine agent most ...
Rheumatoid arthritis (RA) is a systemic inflammatory disease primarily affecting the joints. In the ...
The inability to match rheumatoid arthritis (RA) patients with the anti-cytokine agent most efficaci...
Rheumatoid arthritis (RA) is a chronic systemic disease characterised by inflammation in several joi...
Artículo de publicación SCOPUSTumor necrosis factor (TNF) plays a pivotal role in the pathogenesis ...
Bacground/Aim. Experimental in vitro and in vivo investigations in a mouse model have proved that TN...
Introduction: Currently used clinical scale and laboratory markers to monitor patients with early ...
Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA)...
The aim of the investigation was to study the changes of cytokine profile parameters in patients wit...
OBJECTIVES: To determine the serum concentration of tumour necrosis factor (TNF)-related weak induce...
Background: An important characteristic of immune pathology in rheumatoid arthritis (RA) is a B-cell...
Biologic TNFα inhibitors are a mainstay treatment option for patients with rheumatoid arthritis (RA)...
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily affects small join...
OBJECTIVES: To evaluate synovial tissue and serum biomarkers of disease activity, therapeutic respon...
<p>(<b>A</b>) Plasma levels of TNF-α in HCs, drug responders, and drug non-responders at baseline an...
<div><p>The inability to match rheumatoid arthritis (RA) patients with the anti-cytokine agent most ...
Rheumatoid arthritis (RA) is a systemic inflammatory disease primarily affecting the joints. In the ...
The inability to match rheumatoid arthritis (RA) patients with the anti-cytokine agent most efficaci...
Rheumatoid arthritis (RA) is a chronic systemic disease characterised by inflammation in several joi...
Artículo de publicación SCOPUSTumor necrosis factor (TNF) plays a pivotal role in the pathogenesis ...
Bacground/Aim. Experimental in vitro and in vivo investigations in a mouse model have proved that TN...
Introduction: Currently used clinical scale and laboratory markers to monitor patients with early ...